Reviewer’s report

Title: Efficient delivery of PEGylated liposome IHL-305 into ascites of ovarian cancer peritoneal metastasis in mouse model

Version: 1 Date: 14 June 2012

Reviewer: Li Yang

Reviewer’s report:

This is an interesting and generally well-written paper, which proposed an irinotecan-encapsulated liposome to treat ovarian cancer peritoneal metastasis. However, the manuscript needs to be improved by considering following issues and suggestions.

1. The title of this manuscript is Efficient delivery of PEGylated liposome IHL-305 into ascites of ovarian cancer peritoneal metastasis in mouse model, however, the delivery of PEGylated liposome into ascites is not novel, such as Lin YY, et al. Cancer Biother Radiopharm. 2009. Shmeeda H, et al. J Control Release. 2009. Actually another important finding in this study is CPT-11 or SN-38 exerted a relatively strong cytotoxicity in the spheroids and ascites, so it would be better to modify the title to balance this two findings. (minor essential revisions)

2. In the section Cytotoxic activity of anti-cancer agents against ES-2 cellular spheroids, the reference 23 reported the activities of the anti-cancer agents were reduced in the prostate tumor spheroids, however, it was not invested in the ES-2 cellular model, so it would be better to compare the activities of the anti-cancer agents in monolayer and spheroids culture systems. (minor essential revisions)

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests